NFKB1 and plasma cell myeloma: Moreover 15–20% of myeloma samples also display activating mutations in NF-κB pathway (Ni et al., 2001; Bharti et al., 2004; Annunziata et al., 2007; Keats et al., 2007; Demchenko et al., 2010).